Translational research such as that proposed in the Melanoma and Skin Program (MSCP) SPORE has a spectrum of needs that benefit from software solutions, including clinical information annotation, data warehousing and disease modeling/analysis tools. The informatics Core (Core D) will serve the Projects and Cores of the MSCP SPORE in the following ways: Project 1. CoThe Informatics Core will be responsible for the data extraction and clinical annotations by the Research Information Service (RIS) to support the E1609 patient cohort and ensure the integration of these data into the Research Data Warehouse (RDW) for use by Biostatistics Core (Core C). Project 2. The Informatics Core will assist in studying the management of the toxicities associated with the treatment in the Project 2 cohorts using our clinical phenotyping tool. This project also requires use the Core D's Clinical Trials Management Application (CTMA) and our clinical annotation expertise provided by the RIS. Of note, CTMA will serve all of the Projects' Clinical Research Management System (CRMS) needs. Project 3. Core D will provide access to the clinical annotation data for Project 3 and make these data available to the SPORE team as well as the Biostatistics Core. The study will collect data electronically from our Electronic Medical Record (EMR) systems and analyze it with our cohort discovery tool (GIANT). The research data generated from this project will also be incorporated into our RDW. Project 4. Core D will develop algorithms (via GIANT) to identify patients with in transit melanoma that may be eligible for inclusion in this project and coordinate the collection of clinical annotations from RIS. Core A (Administrative). The Informatics Core will ensure requisite trial data are recorded, stored, backed up, and available for review and annual reporting by the Project PIs to the Internal and External Advisory Boards and the National Cancer Institute. In addition, the Informatics Core will be responsible for all network storage and data sharing within the MSCP SPORE and for Intra-SPORE collaborations and will support the Developmental Research and Career Development Projects managed in Core A.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
4P50CA121973-09
Application #
9091459
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
9
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Anderson, Alyce; Ferris, Laura K; Click, Benjamin et al. (2018) Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci 63:2729-2739
Zhang, Yi; Liu, Zuqiang; Hao, Xingxing et al. (2018) Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model. Cancer Immunol Immunother 67:353-366
Lemchak, David; Banerjee, Swati; Digambar, Shaunak S et al. (2018) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol 27:188-190
Matsumoto, Martha; Secrest, Aaron; Anderson, Alyce et al. (2018) Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol 78:701-709.e1
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Retseck, Janet; Nasr, Alexis; Lin, Yan et al. (2018) Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med 16:184
Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15

Showing the most recent 10 out of 209 publications